Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept Clinical Trial to Investigate OTL-300 in Transfusion-Dependent Beta-Thalassemia Patients

Trial Profile

A Proof of Concept Clinical Trial to Investigate OTL-300 in Transfusion-Dependent Beta-Thalassemia Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OTL 300 (Primary) ; Thiotepa; Treosulfan
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 29 Apr 2019 According to the Orchard Therapeutics media release, data from this trial will be featured in an oral presentation at the 22nd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C. The presentation will report the updated safety and efficacy results of OTL-300 in nine TDT patients.
    • 29 Apr 2019 Results published in the Orchard Therapeutics media release.
    • 15 Apr 2019 According to the Orchard Therapeutics media release, data from this trial will be published online in an abstract via the American Society of Gene & Cell Therapy website and full data set will be featured in an oral presentation at the 22nd ASGCT Annual Meeting 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top